Ensysce Biosciences (ENSC) Cash from Financing Activities (2018 - 2025)

Ensysce Biosciences (ENSC) has reported Cash from Financing Activities for 8 consecutive years, with $1.5 million the latest figure, recorded in Q3 2025.

• In Q3 2025, Cash from Financing Activities fell 64.86% year-over-year to $1.5 million; the TTM figure through Sep 2025 stood at $4.7 million (down 58.26% YoY), while the FY2024 annual figure was $9.9 million, up 12.85% from the prior year.
• Cash from Financing Activities slipped to $1.5 million in Q3 2025 per ENSC's latest filing, from $1.9 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $9.2 million in Q4 2021 and bottomed at -$391270.0 in Q1 2022.
• Historically, Cash from Financing Activities has averaged $2.8 million across 5 years, with a median of $1.9 million in 2025.
• Annual changes were most pronounced in 2022 — Cash from Financing Activities plunged 163.84% — and 2024, when it soared 4131.7%.
• Ensysce Biosciences' Cash from Financing Activities stood at $9.2 million in 2021, then plunged by 78.88% to $1.9 million in 2022, then slipped by 24.7% to $1.5 million in 2023, then sank by 92.3% to $112575.0 in 2024, then soared by 1189.33% to $1.5 million in 2025.
• Business Quant data shows ENSC's Cash from Financing Activities at $1.5 million in Q3 2025, $1.9 million in Q2 2025, and $1.3 million in Q1 2025.